Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.

Gynecologic oncology - 1 Dec 2020

Wichmann Catharina, Klotz Daniel Martin, Zeiler Hans-Joachim, Hilger Ralf Axel, Grützmann Konrad, Krüger Alexander, Aust Daniela, Wimberger Pauline, Kuhlmann Jan Dominik

Abstract excerpt

OBJECTIVES: Extending the therapeutic spectrum of PARP-inhibitors (PARPi) beyond BRCA1-deficiency and/or overcoming PARPi-resistance is of high clinical interest. This is particularly true for the identification of innovative therapeutic strategies for ovarian cancer, given the recent advances in the use of PARPi in clinical practice. In this regard, the combination of PARPi with chemotherapy is a possible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Ovarian Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Recombinational DNA Repair

Share to RNA-Seq

Share to Synthetic Lethal Mutations

Source

Identifiers

PMID: 32980128
DOI: 10.1016/j.ygyno.2020.09.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.PMID 32980128Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian CancerSemantic proximity Read ↗

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.Semantic proximity Read ↗

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian CancerSemantic proximity Read ↗

Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancerSemantic proximity Read ↗

PARP inhibitors as precision medicine for cancer treatmentSemantic proximity Read ↗

Targeting DNA damage repair precision medicine strategies in cancerSemantic proximity Read ↗

PARP Inhibitors for Cancer Therapy.Semantic proximity Read ↗

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian CancerSemantic proximity Read ↗

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesSemantic proximity Read ↗

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.